INVO Fertility, Inc. (IVF): Nasdaq/NYSE listing notice — INVO Bioscience receives Nasdaq delisting notice for equity non-compliance; lease assignment nets $475K

April 17, 2024, the Company, having reported, on April 16, 2024, stockholders’ equity of $892,825 in the Form 10-K for the period ended December 31, 2023, received notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) that requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Equity Rule”). In a decision dated November 22, 2023, a Nasdaq Hearings Panel (the “Panel”) previously had confirmed that the Company reg

On April 19, 2024, INVO Centers LLC ("INVO Centers"), a wholly owned subsidiary of INVO Bioscience, Inc. (the "Company"), completed the assignment to Brown Fertility Associates PA ("Brown Fertility") of its lease with 4602 North Armenia Ave, LLC (the "Landlord"), for the property located at 4602 North Armenia Avenue, Suite 200, Tampa, LLC (the "Premises").